Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2020 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial.
Derby S, Jackson MR, Williams K, Stobo J, Kelly C, Sweeting L, Shad S, Herbert C, Short SC, Williamson A, James A, Nowicki S, Bulbeck H, Chalmers AJ. Derby S, et al. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1371-1378. doi: 10.1016/j.ijrobp.2024.01.011. Epub 2024 Jan 9. Int J Radiat Oncol Biol Phys. 2024. PMID: 38211641 Free article. Clinical Trial.
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw M. Singh K, et al. Nat Med. 2023 Oct;29(10):2402-2405. doi: 10.1038/s41591-023-02464-8. Nat Med. 2023. PMID: 37488293 No abstract available.
Factors affecting the radiation response in glioblastoma.
Aiyappa-Maudsley R, Chalmers AJ, Parsons JL. Aiyappa-Maudsley R, et al. Neurooncol Adv. 2022 Sep 25;4(1):vdac156. doi: 10.1093/noajnl/vdac156. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36325371 Free PMC article. Review.
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, Strathdee K, Cruickshank G, Dunn L, Erridge S, Godfrey L, Jefferies S, McBain C, Sleigh R, McCormick A, Pittman M, Halford S, Chalmers AJ. Hanna C, et al. Neuro Oncol. 2020 Dec 18;22(12):1840-1850. doi: 10.1093/neuonc/noaa104. Neuro Oncol. 2020. PMID: 32347934 Free PMC article. Clinical Trial.
Targeting DNA repair in gliomas.
Beckta JM, Bindra RS, Chalmers AJ. Beckta JM, et al. Curr Opin Neurol. 2019 Dec;32(6):878-885. doi: 10.1097/WCO.0000000000000760. Curr Opin Neurol. 2019. PMID: 31592790 Review.
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.
Fulton B, Short SC, James A, Nowicki S, McBain C, Jefferies S, Kelly C, Stobo J, Morris A, Williamson A, Chalmers AJ. Fulton B, et al. Clin Transl Radiat Oncol. 2017 Nov 21;8:12-16. doi: 10.1016/j.ctro.2017.11.003. eCollection 2018 Jan. Clin Transl Radiat Oncol. 2017. PMID: 29594237 Free PMC article.